These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12588226)

  • 1. Late recurrence of inflammatory first-stage lesions in incontinentia pigmenti: an unusual phenomenon and a fascinating pathologic mechanism.
    Bodak N; Hadj-Rabia S; Hamel-Teillac D; de Prost Y; Bodemer C
    Arch Dermatol; 2003 Feb; 139(2):201-4. PubMed ID: 12588226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incontinentia pigmenti: a review and update on the molecular basis of pathophysiology.
    Berlin AL; Paller AS; Chan LS
    J Am Acad Dermatol; 2002 Aug; 47(2):169-87; quiz 188-90. PubMed ID: 12140463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [From gene to disease; incontinentia pigmenti and the NEMO-gene].
    Oranje AP; Arts WF; Wagner A; van der Hout AH; Simonsz HJ
    Ned Tijdschr Geneeskd; 2005 Jul; 149(30):1682-5. PubMed ID: 16104114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incontinentia pigmenti (Bloch-Sulzberger syndrome).
    Narayanan MJ; Rangasamy S; Narayanan V
    Handb Clin Neurol; 2015; 132():271-80. PubMed ID: 26564087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skin lesion development in a mouse model of incontinentia pigmenti is triggered by NEMO deficiency in epidermal keratinocytes and requires TNF signaling.
    Nenci A; Huth M; Funteh A; Schmidt-Supprian M; Bloch W; Metzger D; Chambon P; Rajewsky K; Krieg T; Haase I; Pasparakis M
    Hum Mol Genet; 2006 Feb; 15(4):531-42. PubMed ID: 16399796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of eotaxin, an eosinophil-selective chemokine, parallels eosinophil accumulation in the vesiculobullous stage of incontinentia pigmenti.
    Jean-Baptiste S; O'Toole EA; Chen M; Guitart J; Paller A; Chan LS
    Clin Exp Immunol; 2002 Mar; 127(3):470-8. PubMed ID: 11966763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serial cytokine expressions in infants with incontinentia pigmenti.
    Liao SL; Lai SH; Huang JL; Lee NC; Lee WI
    Immunobiology; 2013 May; 218(5):772-9. PubMed ID: 23079196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of interaction between NEMO and SHARPIN impairs linear ubiquitination and NF-κB activation and leads to incontinentia pigmenti.
    Bal E; Laplantine E; Hamel Y; Dubosclard V; Boisson B; Pescatore A; Picard C; Hadj-Rabia S; Royer G; Steffann J; Bonnefont JP; Ursini VM; Vabres P; Munnich A; Casanova JL; Bodemer C; Weil R; Agou F; Smahi A
    J Allergy Clin Immunol; 2017 Dec; 140(6):1671-1682.e2. PubMed ID: 28249776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incontinentia Pigmenti with vesicular stage in utero.
    Osório F; Magina S; Nogueira A; Azevedo F
    Dermatol Online J; 2010 Oct; 16(10):13. PubMed ID: 21062607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linear and whorled nevoid hypermelanosis versus incontinentia pigmenti: is pigmentary incontinence really a distinctive feature?
    Delaporte E; Janin A; Blondel V; Copin MC; Piette F; de Martinville B; Bergoend H
    Dermatology; 1996; 192(1):70-2. PubMed ID: 8832959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incontinentia Pigmenti Coxsackium.
    Jefferson J; Grossberg A
    Pediatr Dermatol; 2016 Sep; 33(5):e280-1. PubMed ID: 27396921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incontinentia pigmenti in male patients.
    Pacheco TR; Levy M; Collyer JC; de Parra NP; Parra CA; Garay M; Aprea G; Moreno S; Mancini AJ; Paller AS
    J Am Acad Dermatol; 2006 Aug; 55(2):251-5. PubMed ID: 16844507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent inflammation in incontinentia pigmenti of a seven-year-old child.
    Pfau A; Landthaler M
    Dermatology; 1995; 191(2):161-3. PubMed ID: 8520067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De Novo incontinentia pigmenti in female twins.
    Su PH; Chen JY; Yu JS; Su CM; Huang TC; Chen SJ
    Acta Paediatr Taiwan; 2004; 45(3):178-80. PubMed ID: 15493740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incontinentia pigmenti and hypomelanosis of Ito.
    Bodemer C
    Handb Clin Neurol; 2013; 111():341-7. PubMed ID: 23622185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic use of topical corticosteroids in the vesiculobullous lesions of incontinentia pigmenti.
    Kaya TI; Tursen U; Ikizoglu G
    Clin Exp Dermatol; 2009 Dec; 34(8):e611-3. PubMed ID: 19489863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incontinentia pigmenti: treatment of IP with topical tacrolimus.
    Jessup CJ; Morgan SC; Cohen LM; Viders DE
    J Drugs Dermatol; 2009 Oct; 8(10):944-6. PubMed ID: 19852125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incontinentia pigmenti: a window to the role of NF-kappaB function.
    Bruckner AL
    Semin Cutan Med Surg; 2004 Jun; 23(2):116-24. PubMed ID: 15295921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Incontinentia pigmenti: clinical and neuroimaging findings in a series of 12 patients].
    Pascual-Castroviejo I; Pascual-Pascual SI; Velázquez-Fragua R; Martinez V
    Neurologia; 2006 Jun; 21(5):239-48. PubMed ID: 16788866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incontinentia pigmenti: three cases with unusual features.
    Sahn EE; Davidson LS
    J Am Acad Dermatol; 1994 Nov; 31(5 Pt 2):852-7. PubMed ID: 7962735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.